Sanjay Kumar Sharma, CEO of Biodeal Pharmaceuticals, detailed a strategy to transform Indian healthcare through insurance, innovation, and expanded access [1].
This approach targets one of India's most significant systemic hurdles: the ability to deliver high-quality, affordable medical care to a massive population at scale [1].
Speaking at the Times Network India Health Summit 2026 South Edition, Sharma said how these three pillars can work in tandem to reduce the financial burden on patients [1, 2]. He said that innovation in medical delivery and pharmaceutical development must be paired with robust insurance frameworks to ensure that new treatments reach the people who need them most [1, 2].
Access remains a critical component of the proposed transformation. Sharma said that the ability to scale healthcare depends on removing barriers that prevent rural and underserved populations from receiving care [1, 2]. By integrating innovative technology with wider insurance coverage, the healthcare system can shift from a reactive model to a more sustainable and inclusive one [1, 2].
The summit served as a forum for industry leaders to address the gaps in the current Indian health infrastructure. Sharma's presentation highlighted the necessity of a multi-pronged approach to ensure that affordability does not come at the cost of quality [1, 2].
Biodeal Pharmaceuticals continues to operate within this landscape, focusing on the delivery of pharmaceutical solutions that align with these goals of scalability and accessibility [1, 2].
“Delivering affordable healthcare at scale”
The emphasis on the triad of insurance, innovation, and access reflects a broader shift in Indian healthcare toward universal health coverage. By linking pharmaceutical innovation to insurance mechanisms, the industry aims to move away from out-of-pocket spending, which often prevents millions of citizens from seeking timely medical intervention.
